GleamWall
中文EN

AKBA Akebia Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1517022 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-12.4%
TTM net income YoY-180.2%
TTM EPS YoY-112.5%
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—

Margins

Gross margin78.9%
Operating margin-15.7%
Net margin-22.6%
FCF margin7.0%
EBITDA margin-15.1%

Returns

ROE-143.8%
ROA-12.6%
ROIC (approx.)—
Asset turnover0.56x

Leverage & solvency

Liabilities / assets94.0%
Debt / equity2.47x
Current ratio1.36x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.35x
Accruals ratio-17.1%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$36.90M$49.13M$53.54M$57.62M$58.77M$62.47M$57.34M$46.50M
Cost of revenue$6.36M$10.42M$12.29M$12.54M$9.38M$9.92M$7.62M$20.36M
Gross profit$30.54M$38.70M$41.25M$45.09M$49.38M$52.55M$49.71M$26.13M
R&D expense$16.18M$14.06M$14.81M$26.65M$14.94M$11.01M$9.75M$11.79M
SG&A expense$23.53M$28.17M$30.44M$26.09M$29.09M$26.55M$25.74M$27.68M
Operating income-$11.46M-$6.33M-$4.70M-$8.55M$4.45M$14.09M$13.51M-$14.31M
Pretax income-$14.18M-$8.84M-$8.93M-$11.23M$1.16M$247,000$6.11M-$22.80M
Income tax$175,000$70,000$126,000$1.01M$615,000$0$0$0
Net income-$14.35M-$8.91M-$9.05M-$12.24M$540,000$247,000$6.11M-$22.80M
EBITDA-$11.36M-$5.74M-$4.37M-$8.23M$4.77M$14.40M$13.83M-$13.97M
EPS (basic)-0.05-0.03-0.03—0.000.000.03—
EPS (diluted)-0.05-0.03-0.03—0.000.000.03—
Weighted avg. shares (diluted)276.86M269.60M267.05M—274.37M271.10M241.60M—
Balance sheet
Cash & equivalents$159.25M$155.55M$162.64M$184.84M$168.14M$139.00M$115.06M$53.55M
Receivables$36.44M$53.51M$62.54M$47.03M$66.22M$72.81M$61.54M$34.37M
Inventory$18.70M$13.02M$13.00M$15.61M$18.64M$16.71M$19.73M$16.24M
Current assets$220.78M$229.55M$243.48M$252.96M$258.34M$234.66M$203.78M$113.83M
PP&E, net$2.40M$1.51M$956,000$1.22M$1.47M$1.71M$1.90M$2.20M
Goodwill$59.04M$59.04M$59.04M$59.04M$59.04M$59.04M$59.04M$59.04M
Intangibles———————$0
Total assets$342.13M$349.66M$362.52M$376.56M$364.15M$345.60M$310.19M$220.67M
Current liabilities$162.35M$160.87M$173.88M$162.94M$133.38M$118.72M$91.23M$80.91M
Short-term debt$37.49M$24.81M$12.49M$0———$0
Long-term debt$12.78M$24.75M$36.40M$48.25M$47.64M$47.06M$46.51M$38.69M
Total debt$50.27M$49.56M$48.89M$48.25M$47.64M$47.06M$46.51M$38.69M
Total liabilities$321.76M$324.64M$335.14M$343.95M$322.56M$316.37M$285.60M$269.86M
Shareholders' equity$20.37M$25.02M$27.38M$32.61M$41.59M$29.22M$24.58M-$49.19M
Net debt-$108.98M-$105.98M-$113.75M-$136.59M-$120.50M-$91.94M-$68.55M-$14.86M
Shares outstanding277.52M271.74M267.90M265.42M265.23M263.04M261.64M224.85M
Cash flow statement
Operating cash flow$2.33M$3.52M-$21.21M$31.13M$28.11M$22.34M-$13.59M-$4.47M
Capital expenditure$706,000$1.08M$62,000$70,000$77,000$126,000$18,000$2,000
Free cash flow$1.63M$2.45M-$21.27M$31.06M$28.03M$22.22M-$13.61M-$4.47M
Investing cash flow-$2.61M-$4.08M-$62,000-$7.88M-$77,000-$126,000$154,000-$2,000
Financing cash flow$3.18M-$6.54M-$926,000-$4.85M$1.11M$1.72M$74.94M$22.32M
Depreciation & amortization$101,000$585,000$328,000$321,000$318,000$316,000$314,000$335,000
Stock-based compensation$2.80M$3.23M$3.67M$3.20M$3.22M$2.68M$2.19M$1.70M

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.